Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma
Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further investigation of VXM01 BASEL, Switzerland, March 26, 2025 /PRNewswire/ -- Vaximm AG, a...
OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer
BASEL, Switzerland, March 25, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the...
OSR Holdings, Inc. and OSR Holdings Co., Ltd. Announce Completion of Business Combination
OSR Holdings, Inc. to Begin Trading on the Nasdaq Stock Market LLC on Tuesday, February 18, 2025 Under the symbol "OSRH" SEOUL, South Korea, Feb. 15, 2025 /PRNewswire/ -- OSR Holdings, Inc. (formerly Bellevue Life Sciences Acquisition Corp. (the...
Bellevue Life Sciences Acquisition Corp. Announces Approval of Business Combination Proposal And Name Change to OSR Holdings, Inc.
SEOUL, South Korea, Feb. 14, 2025 /PRNewswire/ -- Bellevue Life Sciences Acquisition Corp. ("BLAC") announced today the approval of each of the proposals presented at the special meeting of its stockholders (the "Special Meeting") held today,...